US FDA’s Stance On CBD In Cosmetics Hasn’t Changed, And Neither Have Marketing Challenges
Executive Summary
The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.
You may also be interested in...
US FDA’s Cosmetics Director Katz Cites Fragrance Allergens, Talc-Containing Products Among Priorities
Linda Katz, director of the US FDA’s Office of Cosmetics and Colors, offered insight into priority cosmetics issues at the Independent Beauty Association’s virtual FDA Cosmetic Regulations Workshop.
ICMAD Rebrands As Independent Beauty Association Ahead Of Annual FDA Regulations Workshop
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.
US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level
As it recently told Congress it would, FDA reopens docket on “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived,. "Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb," says NPA head Daniel Fabricant.